Envestnet Asset Management Inc. reduced its position in DaVita Inc. (NYSE:DVA - Free Report) by 49.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,207 shares of the company's stock after selling 50,728 shares during the quarter. Envestnet Asset Management Inc. owned about 0.06% of DaVita worth $7,658,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new position in shares of DaVita in the fourth quarter valued at approximately $41,000. Venturi Wealth Management LLC increased its position in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after purchasing an additional 152 shares during the last quarter. Versant Capital Management Inc increased its position in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after purchasing an additional 169 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after purchasing an additional 131 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in shares of DaVita by 28.6% during the fourth quarter. Jones Financial Companies Lllp now owns 517 shares of the company's stock worth $77,000 after purchasing an additional 115 shares during the period. Institutional investors and hedge funds own 90.12% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have commented on DVA. Barclays increased their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, DaVita currently has an average rating of "Hold" and an average price target of $166.33.
Check Out Our Latest Analysis on DVA
DaVita Price Performance
Shares of NYSE DVA traded up $0.01 during trading hours on Thursday, reaching $138.94. 125,919 shares of the stock traded hands, compared to its average volume of 836,460. The company's 50-day simple moving average is $147.16 and its two-hundred day simple moving average is $155.53. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52-week low of $130.96 and a 52-week high of $179.60. The company has a market capitalization of $11.12 billion, a P/E ratio of 12.95, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
